Media Center
Bacteriophage Pipeline Seminar on February 22, 2022.
Date：2022-11-30
On the afternoon of February 22, 2022, at 2:00 PM, the "Bacteriophage Therapy R&D Pipeline Seminar" was successfully held at Zhongshan Hospital. The seminar was jointly organized by Zhongshan Hospital affiliated with Fudan University, CreatiPhage, Shanghai Phage and Antimicrobial Resistance Research Institute, Ultraordinary (Shanghai) Medical Technology Co., Ltd., and Fenglin Medical Innovation. The event invited over 20 experts and scholars from the field of bacteriophage research, as well as representatives from the Shanghai Center for Drug Evaluation and Inspection, the Shanghai Municipal Health Commission, and Zhongshan Hospital affiliated with Fudan University, to provide guidance and share insights.
Firstly, Professor Zhu Tongyu, Deputy Dean of Fudan University's Medical School, Director of the Medical Services Professional Committee of the Shanghai Modern Service Industry Federation, and representative of the scientific team for the bacteriophage project, elaborated on the specific bactericidal action of bacteriophages in the field of antimicrobials. As the most abundant microbial resource in nature, bacteriophages are one of the key solutions to the problem of bacterial resistance in the "post-antibiotic" era, possessing significant clinical value and a broad market application value. Professor Zhu Tongyu addressed the increasingly severe issue of antimicrobial resistance faced globally, and by integrating research findings from industry leaders and various governments, he provided an insightful analysis of the immense potential of bacteriophages in clinical applications.
Professor Zhu Tongyu raised the increasingly severe issue of antimicrobial resistance faced globally, and by incorporating research conclusions from industry leaders and governments worldwide, he provided a clear and profound analysis of the significant potential of bacteriophages in clinical applications.
In 1958, Shanghai witnessed the first case of bacteriophage therapy in China. Sixty years later, led by Professor Zhu Tongyu, Guo Xiaokui, and Chen Liguang of the Shanghai Phage and Antimicrobial Resistance Research Institute, the second case of bacteriophage treatment in China was realized in 2018. Since then, the institute has become the most influential bacteriophage clinical application institution in the country. By the end of 2021, it had successfully treated 85 cases of drug-resistant bacterial infections from across the nation, published a series of original clinical and basic research papers, and organized national continuing education and training on bacteriophage prevention and treatment of antimicrobial resistance for four consecutive years, positioning itself as a leader domestically and running alongside international counterparts.
Subsequently, Dr. Nan Nan Wu, the Chief Scientist and co-founder of CreatiPhage, introduced the company's leading achievements in clinical research and treatment as the enterprise with the most comprehensive bacteriophage library in China. Today, the global bacteriophage industry is progressing rapidly, showcasing a wide range of application scenarios and significant commercial potential.
CreatiPhage possesses a well-established bacteriophage & bacteria library, high-throughput bacteriophage screening technology, and advanced gene-editing bacteriophage techniques. The company aims to develop new drugs and personalized bacteriophage therapies based on bacteriophages and their encoded products, as Class III medical technologies. It is committed to developing a product pipeline for the prevention and treatment of bacterial infections in clinical applications, environmental disinfection, home personal care, and expanded fields.
Finally, all parties at the meeting expressed their admiration for the company's achievements and contributions to society and the medical community. They also engaged in a positive discussion about the future development of products and service pipelines.
Leaders from the Shanghai Center for Drug Evaluation and Inspection and the Shanghai Municipal Health Commission provided professional opinions on the technical aspects and points to consider for application processes. They encouraged CreatiPhage to actively explore new industrialization fields, to simultaneously implement various pipelines and methods including medical technologies, bacteriophage libraries, and devices, and to accumulate and analyze data on safety and efficacy during the pre-clinical research process.
The conference concluded successfully in a positive and harmonious atmosphere, with participants speaking freely and building a consensus on the bacteriophage industry and the industry representative, CreatiPhage. This meeting was just the beginning, initiating a healthy ecosystem of research and development, industry, regulation, and market, and laying a solid foundation for addressing the "gray rhino" issue of antimicrobial resistance infections in humans.
Add: 3333 Huaning Road, Shanghai
Tel: 0086-400-668-7738
©Shanghai ICP reserve No. 2022031782-1 CreatiPhage Biotechnology Co., Ltd. All rights reserved. Designed by JCE
